Jubilant HollisterStier (JHS) has been informed by the FDA that its pharmaceutical sterile manufacturing facility in Spokane, WA has been upgraded to the status of Voluntary Action Indicated (VAI). The Spokane site’s Establishment Inspection Report (EIR) indicates that inspections conducted in April 2014 and December 2014 have been successfully concluded. This upgrade by the FDA from Official Action Indicated (OAI) to VAI is indicative of the cGMP status at the facility since a warning letter was issued in 2013.
Mr. Shyam S Bhartia, Chairman and Mr Hari S Bhartia, Co-Chairman & Managing Director, of JHS’ parent company, Jubilant Life Sciences, commented, “Jubilant remains committed to continuous improvements to maintain compliance at all its pharmaceutical manufacturing facilities across the globe. We consider this development as another step towards building a reliable and sustainable pharmaceutical business.”
Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery. With 10 world-class manufacturing facilities in India, US and Canada, and a team of about 6,200 multicultural people across the globe, Jubilant Life Sciences is committed to delivering value to its customers. JHS is a Founding Member of the Pharma & Biopharma Outsourcing Association.
